Lilly unveils early long-term data on eczema drug that could chip away at Dupixent market
As it looks to bring lebrikizumab to market, Eli Lilly shared initial one-year data for 10 patients on its atopic dermatitis drug.
Of the 10 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
